HALO
NASDAQ
$77.09
Halozyme Therapeutics Inc (HALO)
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $83.90 (+8.83%)
Market Cap
$8.99B
EPS 5Y CAGR
+20.06%
Revenue 5Y CAGR
+35.42%
FCF 5Y CAGR
+41.93%
Price Chart
Valuation
Market Cap$8.99B
P/E25.62
Forward P/E10.78
P/S5.90
P/B41.10
Profitability
Total Revenue (TTM)$1.51B
Gross Profit (TTM)$1.16B
EBITDA$525M
Profit Margin39.8%
Operating Margin49%
EPS$2.96
Financial Health
Debt-to-Equity976.5%
Free Cash Flow Yield7.43%
Growth & Risk
EPS 5Y CAGR+20.06%
Revenue 5Y CAGR+35.42%
FCF 5Y CAGR+41.93%
Beta (5Y)0.62
Sharpe Ratio0.97